Principal Scientist, Immunology

What if… you could join an organization that creates, resources, and builds life sciences companies that invent breakthrough technologies to transform human health and sustainability?

Flagship Pioneering's venture creation engine has conceived and created companies such as Moderna Therapeutics (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Sana Biotechnology (NASDAQ: SANA), Generate Biomedicines, and Tessera Therapeutics. Since its launch in 2000, Flagship has applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $212 billion in aggregate value. To date, Flagship has deployed over $2.5 billion in capital toward the founding and growth of its pioneering companies alongside more than $19 billion of follow-on investments from other institutions. In 2021, Flagship Pioneering was ranked 12th globally on Fortune’s “Change the World” list, an annual ranking of companies that have made a positive social and environmental impact through activities that are part of their core business strategies.

The Company:

Quotient Therapeutics is a privately held, early-stage company developing a novel genomics platform and therapeutics for diseases with a large unmet need.

Position Summary:

Quotient Therapeutics seeking a Senior Scientist with a strong immunology background, who will be responsible for the translational validation of discovery platform targets in cell-based and disease-relevant pharmacological models.

The ideal candidate will be a talented, goal-oriented and highly motivated individual who will play a vital role in the company’s efforts to progress early discovery projects in inflammatory and autoimmune diseases. They will have a strong background in immunology, autoimmune diseases and drug discovery, with experience leading early discovery projects.  The successful candidate would thrive in a highly dynamic, fast-paced and cross-functional team environment. Excellent communication skills, independence and open-mindedness are highly valued.

Key Responsibilities:

• Contribute to and lead Immunology activities across multiple autoimmune-based projects in the early discovery phase
• Work both independently and in collaboration with cross-functional teams and CROs to ensure timely delivery of project milestones
• Lead the design and interpretation of somatic genomics platform studies for identification of novel targets in a range of autoimmune disease areas
• Design and implement robust in vitro and in vivo pharmacological models to validate target mechanisms and translational relevance to human disease
• Evaluate and align modalities with target mechanisms and define hit identification strategies
• Assess target engagement, in vitro pharmacology, in vivo PK/PD assessment and biomarker plans in preparation for drug candidate selection
• Utilize creativity and critical thinking skills to identify assays, troubleshoot/optimize experiments and to interpret data to drive go/no go decisions
• Must display attention to detail, sense of urgency and ”outside the box” thinking

Qualifications:

• Ph.D. in Immunology, Biochemistry, Molecular Biology, or a related discipline with at least 8 years of industry experience, with a focus on autoimmune disease (title will be adjusted for the level of experience)
• Deep knowledge and understanding of cellular and molecular biology techniques. Proficient in experimental design, assay execution, troubleshooting, data analysis, and data interpretation
• Strong expertise in drug target validation and immunological assays using primary tissues and primary human blood, preferably primary human B and T cells
• Experience in FACS, cell culture, RT-qPCR, western blots and cell-based genetic manipulation (e.g., knockdown, knockout, overexpression) is a must. Proficiency with RNA-seq, cloning and image analysis are highly preferred
• Strong written and oral presentation skills
• Execution focused, team oriented, and highly motivated

Location: Cambridge, MA 

About Flagship

Flagship Pioneering is a bioplatform innovation company that invents and builds platform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $90 billion in aggregate value. Many of the companies Flagship has founded have addressed humanity’s most urgent challenges: vaccinating billions of people against COVID-19, curing intractable diseases, improving human health, preempting illness, and feeding the world by improving the resiliency and sustainability of agriculture.  Flagship has been recognized twice on FORTUNE’s “Change the World” list, an annual ranking of companies that have made a positive social and environmental impact through activities that are part of their core business strategies, and has been twice named to Fast Company’s annual list of the World’s Most Innovative Companies. Learn more about Flagship at www.flagshippioneering.com.